Targeting Peptide Guides Cancer Drug Directly to Pancreatic Tumors Using Nanoliposomes
A CKAAKN peptide-conjugated nanoliposome selectively delivered the anti-cancer compound oridonin to pancreatic cancer cells, showing enhanced tumor uptake and significantly improved antitumor effects in vitro and in vivo.
Quick Facts
What This Study Found
The CKAAKN peptide-conjugated nanoliposome (ORI@CPD-Lipo) demonstrated:
- Average particle size of ~100 nm with good stability and biosafety
- Selective internalization into BxPC-3 pancreatic cancer cells within 1–4 hours in vitro, compared to minimal uptake in normal HPDE6-C7 cells
- Significantly higher tumor uptake in vivo over 1–48 hours compared to normal pancreatic tissue, with increasing ratios over time
- Enhanced antitumor effect compared to free oridonin, non-targeting liposomes, and CKAAKN-blocked controls
- The enhanced activity was attributed to peptide-mediated cellular uptake and sustained drug release from nanoparticles
Key Numbers
How They Did This
Researchers developed PEGylated nanoliposomes modified with the CKAAKN tumor-targeting peptide to deliver oridonin. The formulation was characterized for size, stability, and safety. In vitro studies compared uptake in pancreatic cancer cells (BxPC-3) versus normal cells (HPDE6-C7). In vivo biodistribution was assessed in tumor-bearing mice. Antitumor efficacy was compared across free drug, non-targeting liposomes, targeted liposomes, and CKAAKN-blocked controls.
Why This Research Matters
Pancreatic cancer has one of the worst survival rates of any cancer, partly because drugs don't reach the tumor effectively. Using a targeting peptide to guide drug-loaded nanoparticles directly to cancer cells could significantly improve treatment efficacy while reducing side effects from off-target drug exposure. This peptide-targeted approach is applicable beyond oridonin to other anti-cancer agents.
The Bigger Picture
Peptide-targeted drug delivery is an active area of cancer nanotechnology research. The CKAAKN peptide specifically recognizes pancreatic cancer cells, making it a valuable targeting ligand. This study demonstrates the viability of combining targeting peptides with nanoliposome technology to improve chemotherapy delivery, an approach being explored for multiple cancer types.
What This Study Doesn't Tell Us
This is a preclinical study using cell lines and mouse xenograft models, which may not fully reflect human pancreatic cancer complexity. The oridonin payload is a natural compound with limited clinical validation. Long-term safety, pharmacokinetics, and potential immunogenicity of the peptide-conjugated nanoliposomes in humans are unknown. Manufacturing scalability of the targeted nanoformulation was not addressed.
Questions This Raises
- ?Could CKAAKN peptide-targeted nanoliposomes deliver more established chemotherapy drugs like gemcitabine to pancreatic tumors?
- ?How does the immune system respond to repeated administration of peptide-conjugated nanoliposomes?
- ?What is the maximum therapeutic index improvement achievable with peptide-targeted versus untargeted drug delivery in pancreatic cancer?
Trust & Context
- Key Stat:
- Selective tumor uptake over 48 hours CKAAKN peptide-conjugated nanoliposomes accumulated preferentially in pancreatic tumors versus normal tissue, with increasing ratios over time
- Evidence Grade:
- This is a preclinical study with in vitro cell culture and in vivo mouse xenograft data. While it demonstrates proof-of-concept for peptide-targeted delivery, no human testing has been conducted.
- Study Age:
- Published in 2026, this is very recent work in the active field of peptide-targeted cancer nanomedicine.
- Original Title:
- CKAAKN peptide-conjugated long-circulating nanoliposomes for the targeted delivery of oridonin to pancreatic cancers.
- Published In:
- Scientific reports, 16(1), 6065 (2026)
- Authors:
- Zhang, Fangxia, Luo, Kunshun, Xuan, Shaoyan, Chen, Teng, Chen, Zhiyong, Yang, Jing, Zhou, Ying, Feng, Tingting, Zhu, Yue, Wang, Zuhua
- Database ID:
- RPEP-16543
Evidence Hierarchy
Frequently Asked Questions
How does the CKAAKN peptide target pancreatic cancer?
The CKAAKN peptide specifically recognizes and binds to molecules on the surface of pancreatic cancer cells that aren't present (or are less common) on normal cells. When attached to drug-carrying nanoparticles, it guides them preferentially to the tumor, increasing drug delivery to cancer cells while sparing healthy tissue.
Could this approach work for other types of cancer?
The nanoliposome platform could be adapted for other cancers by using different targeting peptides specific to those tumor types. The CKAAKN peptide is specific to pancreatic cancer, but similar peptide-targeting strategies are being developed for breast, lung, and other cancers.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-16543APA
Zhang, Fangxia; Luo, Kunshun; Xuan, Shaoyan; Chen, Teng; Chen, Zhiyong; Yang, Jing; Zhou, Ying; Feng, Tingting; Zhu, Yue; Wang, Zuhua. (2026). CKAAKN peptide-conjugated long-circulating nanoliposomes for the targeted delivery of oridonin to pancreatic cancers.. Scientific reports, 16(1), 6065. https://doi.org/10.1038/s41598-026-36920-5
MLA
Zhang, Fangxia, et al. "CKAAKN peptide-conjugated long-circulating nanoliposomes for the targeted delivery of oridonin to pancreatic cancers.." Scientific reports, 2026. https://doi.org/10.1038/s41598-026-36920-5
RethinkPeptides
RethinkPeptides Research Database. "CKAAKN peptide-conjugated long-circulating nanoliposomes for..." RPEP-16543. Retrieved from https://rethinkpeptides.com/research/zhang-2026-ckaakn-peptideconjugated-longcirculating-nanoliposomes
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.